

Abstracts (Stand 02/2025)

- A 044** Villano Bonamin L, Novaes Fontao Lefebvre G, Neves Gardoso T, Reif M. Two cases reports comparing histopathological features of canine transmissible venereal tumor after treatment with decimal potencies of Viscum Album and Vincristin. International Journal of High Dilution Research 2015; 14(2): 55-56 Proceedings of the XXIX GIRI Meeting; 2015 June 3-5; Verona (Italy)
- A 043** Quittel F, Zerm R, Reif M, Büssing A, Gutenbrunner Ch, Kröz M. Long-term effects on Quality of life of a Multimodal Therapy in Breast Cancer patients with Fatigue. European Journal of Integrative Medicine 2021;48:101937. doi: 10.1016/j.eujim.2021.101936
- A 042** Kröz M, Brinkhaus B, Reif M, Klaus A-K, Zerm R, Ostermann T. Reliability and validity of the German State autonomic regulation questionnaire in geriatric persons. European Journal of Integrative Medicine 2021;48:102066. doi:10.1016/j.eujim.2021.102065
- A 041** Klaus A K, Zerm R, Mehl A, Ostermann T, Rodrigues Recchia D, Reif M, von Laue H B, Brinkhaus B, Kröz M: VALIDATION OF THE CANCER FATIGUE SCALE IN A GERIATRIC POPULATION. Abstract 311 Deutscher Krebskongress 2020 in Berlin
- A 040** Zerm R, Glinz A, Pranga D, Berger B, ten Brink F, Reif M, Büssing A, Gutenbrunner Ch, Kröz M: Impact of a multimodal treatment on the actigraphically measured activity pattern in breast cancer patients with cancer related fatigue. BMC Complementary and Alternative Medicine P205; 17(Suppl 1):317; 2017
- A 039** Kröz M, Didwiszus A, Gelin-Kröz B, Pranga D, Reif M, Brink F, Zerm R, Gutenbrunner C, Büssing A: Reliability of the inner correspondence and harmony questionnaire with painting therapy (ICPTh). European Journal of Integrative Medicine 8S; 1-66; 2016
- A 038** Kröz M, Reif M, Glinz A, Berger B, Nikolaou A, Zerm R, Brinkhaus B, Girke M, Büssing A, Gutenbrunner C: Multimodal and combined multimodal-aerobic therapy in breast survivors with cancer-related fatigue. Journal of Clinical Oncology, ASCO Annual Meeting 29.05.2015-02.06.2015
- A 037** Tröger W, Galun D, Reif M, Schumann A, Stancović N, Milićević M: Mistletoe Therapy For Patients With Advanced Pancreatic Cancer: Overall Survival And Quality Of Life. 7th ECIM, Belgrad, 10.-11. Oktober 2014
- A 036** Tröger W, Reif M, Galun D, Schumann A, Stancović N, Milićević M: Viscum album [L.] extract therapy versus no antineoplastic therapy in patients with locally advanced or metastatic pancreatic cancer: a randomized confirmatory clinical trial (ISRCTN 70760582). MASCC 2013

Entspricht
Z 056

- A 035** Galun D, Tröger W, Reif M, Schumann A, Stancović N, Milićević M: Viscum album [L.] extract therapy versus no antineoplastic therapy in patients with locally advanced or metastatic pancreatic cancer: a randomized confirmatory clinical trial (ISRCTN 70760582). 10th E-AHPBA 2013
Entspricht Z 057
- A 034** Tröger W, Reif M Galun D, Schumann A, Stancović N, Milićević M: Viscum album [L.] Extract-Therapie versus keine antineoplastische Therapie bei Patienten in lokal fortgeschrittenem oder metastasiertem Stadium des Pankreas-Karzinoms: Eine randomisierte konfirmative klinische Studie. ASORS Kongress 2013
Entspricht Z 055
- A 033** Reif M: Kohortenstudien als Grundlage für erweiterte Erkenntnisse der Wirksamkeit pflanzlicher Präparate am Beispiel der Mistel. Abstract in Evidence-based Medicine und pragmatische Forschung in der Phytotherapie 28. Schweizerische Tagung für Phytotherapie, Baden 21. November 2013
Entspricht Z 052
- A 032** Kröz M, Reif M, Zerm R, Winter K C, Candir F, Quetz M, Brinkhaus B, Girke M, Gutenbrunner C: The concept of a new multimodal approach based on Anthroposophic Medicine in the treatment of chronic cancer-related-fatigue in breast cancer patients. Abstract in Research in Complementary Medicine, Vol. 20, suppl. 3, 2013: OP-211
- A 031** Kröz M, Zerm R, Reif M, von Laue H B, Schad F, Matthes H, Brinkhaus B, Girke M: Autonomic regulation – a psychometric concept for the measurement of hygiogeneseis. Abstract in Research in Complementary Medicine, Vol. 20, suppl. 3, 2013: OP-210
- A 030** Cesari M, Longhi A, Ferrari S, Reif M: Viscum album fermentatum pini versus oral etoposide as adjuvant treatment in osteosarcoma patients after second relapse. Abstract in European Journal of Integrative Medicine, Vol. 4, suppl. 1, 2012: OP-008
- A 029** Galun D, Tröger W, Reif M, Schumann A, Stancović N, Milićević M: Phase III trial on mistletoe extract versus no antineoplastic therapy in patients with locally advanced or metastatic pancreatic cancer. Abstract in European Journal of Integrative Medicine, Vol. 4, suppl. 1, 2012: OP-007
- A 028** Krötz M, Zerm R, Reif M, Broder von Laue H, Zander A, Schad F, Brinkhaus B, Matthes H, Girke M: Are autonomic regulation (aR) and self-regulation predictors for internal coherence and distress in internal medicine patients? Abstract in European Journal of Integrative Medicine, Vol. 4, suppl. 1, 2012: OP-252
- A 027** Kanitz J L, Reif M, Rihs C, Krause I, Seeger K, Seifert G: Improvements of Well-being after one Single Rhytmical Massage Intervention in Stressed Adults – a Prospective, Randomised, Three Armed Study. Abstract in European Journal of Integrative Medicine , Vol. 4, suppl. 1, 2012: OP-163
- A 026** Kanitz J L, Pretzer K, Reif M, Witt K, Reulecke S, Voss A, Längler A, Henze G, Seifert G: The impact of eurythmy therapy on fatigue in healthy adults – A controlled trial. Abstract in European Journal of Intrgrative Medicine , Vol. 4, Issue 3, 2012, Pages e289-e297

- A 025** Zajicek J, Reif M, Schnelle M, on behalf of the UK MUSEC Study Investigators: Cannabis extract in the treatment of muscle stiffness and other symptoms in multiple sclerosis – results of the MUSEC study. Abstract ECTRIMS, 25th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis, September 9-12, 2009, Düsseldorf, Germany
Entspricht P 010
- A 024** Schnelle, M: Cannabis as Medicine. Abstract Symposium about Industrial Hemp at the Swedish University of Agricultural Sciences, Alnarp, 30. August 2001, 25:29
- A 023** Gorter RW: Viscum album L. (aqueous extract) as an immunomodulator and antiviral drug in HIV. A Phase II Trial. Abstract 12th World AIDS Conference Geneva 28. Juni-3. Juli 1998
Entspricht Z 005
- A 022** Kröz M, Büsing A, von Laue HB, Reif M, Feder G, Schad F, Girke M, Matthes H: Reliability and validity of a new scale on internal coherence (ICS) of cancer patients. Abstract in Health and Quality of Life Outcomes 2009, 7:59
Entspricht Z 040
- A 021** Reif M, Kröz M, Schad F, von Laue HB, Feder G, Matthes H, Girke M: Classification procedure of the German version of the Cancer Fatigue Scale (CFS-D). Abstract ASCO Annual Meeting 2009, J Clin Oncol 27, 2009 (suppl; abstr e20608)
- A 020** Kröz M, Kuhnert N, Brauer D, von Laue HB, Bockelbrink A, Reif M, Heckmann C, Girke M: Cancer Fatigue und gestörte Ruhe/Aktivitätsregulation bei rezidivfreien Mammakarzinom Patientinnen, Ergebnisse einer prospektiven Studie. Abstracts des 114. Internistenkongresses 2008 , Medizinische Klinik, Vol. 103, Suppl. 1: 192
- A 019** Strasser F, Lueftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W, Ko Y-D, Schnelle M, Reif M, Cerny T: Oral Cannabis-Extract (CE) Versus Delta-9-Tetrahydrocannabinol (THC) For Patients with Cancer-Related Anorexia (CRA): A Randomized, Double Blind, Placebo-Controlled, Multicenter Study. International Association for Cannabis as Medicine (IACM) 2nd conference on Cannabinoids in Medicine, Cologne, 12-13 September 2003
- A 018** Nadulski T, Pragst F, Weinberg G, Roser P, Schnelle M, Fronk EM, Stadelmann AM: Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of delta-9-tetrahydrocannabinol (THC) after oral application of THC vs. standardized cannabis extract. International Association for Cannabis as Medicine (IACM) 3rd conference on Cannabinoids in Medicine, Leiden, 9.- 10. September 2005, <http://www.acmed.org/german/nav/home-conference.htm> , Leiden 2005
- A 017** Ernst G, Denke C, Reif M, Schnelle M, Hagmeister H: Standardized cannabis extract in the treatment of postherpetic neuralgia – a randomized, double-blind, placebo-controlled cross-over study. World Congress on Pain, Sydney, 21.- 26. August 2005
- A 016** Kröz M, von Laue H, Zerm R, Reif M, Gierke M, Heckmann C: A new long version of trait marker questionnaire for endogenous regulation.; Program & Abstracts, 1st World Congress of Chronobiologie. Sapporo, 2003, pp 73

- A 015** Helwig S, Fronk ES, Reif M, Schnelle M, Hoffmann J: Maximally tolerated dose (MTD) of standardized cannabis extract in palliative cancer patients: preliminary results from an open-label, non-randomized phase I/II trial. International Association for Cannabis as Medicine (IACM) 2nd conference on Cannabinoids in Medicine, Köln, 12.-13 September 2003, <http://www.acmed.org/german/nav/home-conference.htm> : Cologne 2003, Reader, p. 21
- A 014** Büsing A, Bischof M, Hatzmann W, Bartsch F, Soto Vera D, Fronk EM, Gmeindl M, Stein GM: Hemmung der operations-assoziierten Depression der Granulozytenfunktion durch eine einmalige peri-operative intravenöse Applikation eines Viscum Album L.-Extraktes. 3. Mistelsymposium Nonnweiler, 20.-22. November 2003, Abstractband: 23
- A 013** Wispler M, Kappler M, Soto Vera D, Reif M, Schnelle M, Zänker KS: Prospektive, randomisierte, teilkontrollierte Studie zur Aktivierung des Homings und des allgemeinen Aktivitätsniveaus von T-Lymphozyten durch subkutane Mistel-Extrakt-Injektionen bei gesunden männlichen Probanden. 3. Mistelsymposium Nonnweiler, 20.-22. November 2003, Abstractband: 18
- A 012** Kröz M, Zerm R, Laue HB von, Brauer D, Reif M, Heckmann C, Girke M: Regulationsverlust internistischer Patienten gemessen mit einem neuen Fragebogen zur endogenen Regulation. 109. Jahrestagung der DGIM (Deutsche Gesellschaft für Innere Medizin), Wiesbaden, 26.-30. April 2003, Medizinische Klinik 98, Abstractband
- A 011** Büsing A, Stein GM, Bischof M, Hatzmann W, Bartsch F, Soto-Vera D, Fronk EM, Gmeindl M: Prevention of surgery induced depression of granulocyte function by intravenous application of a viscotoxin-containing extract from Viscum album L. 12. AEK Cancer Congress (Arbeitsgemeinschaft Experimentelle Krebsforschung), Würzburg, 25.-28. März 2003, Abstractband: 167
- A 010** Cerny T, Lueftner D, Possinger K, Ernst G, Ruhstaller T, Meissner M, Ko YD, Schnelle M, Reif M, Strasser F: Oral cannabis-extract (CE) versus delta-9-tetrahydrocannabinol (THC) for patients with cancer-related anorexia (CRA): A randomized, double-blind, placebo-controlled multicenter study. 39th Annual Meeting of the American Society for Clinical Oncology (ASCO), Chicago, May 31-June 3, 2003, Abstract # 101798
- A 009** Strasser F, Schnelle M, Kuechler T, Reif M, Cerny T: How to study patients with cancer anorexia/cachexia syndrome (CCS): "work in progress report" from a placebo-controlled phase III trial with emphasis on the difficulties to define an adequate patient population and on the development of outcome measurement instruments. 1. Kongress des Research Network der European Association for Palliative Care, Berlin 7.-9. Dezember 2000, J Pain Sympt Managem 29 (6): S66
- A 008** Gorter RW, Stoss M, Peter E, Soto Vera D: Prospective, open-label phase-II-study to document the immunomodulatory and anti-HIV-activity of Va QuFrF in HIV-positives over 11 months. 7. Deutscher AIDS-Kongreß, Essen, 2.-6. Juni 1999, European Journal of Medical Research 4 (Suppl I): 10

- A 007** Gorter RW, Rotty J, Heinzerling L, Schnelle M: The immunomodulating activities of Iscador Qu special (Viscum album) in patients with HPV-associated cervical dysplasia. 1st Scientific Conference, Zakopane, March 5-8, 1998, Abstract book: 217
- A 006** Gorter RW: Cannabis und chronische Schmerzen. Der Deutsche Schmerztag 1998. 9. Deutscher interdisziplinärer Schmerzkongreß. Frankfurt a. M., 4.-8. März 1998, Abstractband: 26-27
- A 005** Gorter RW, Schnelle M, Stoss M, v. Wely M: Cannabis and wasting in AIDS and cancer. 1997 Symposium on the Cannabinoids. International Cannabinoid Research Society (ICRS), Stone Mountain, Georgia, June 20-22, 1997, Abstract book: 87
- A 004** v. Wely M, Stoss M, Gorter RW: Open-label Phase-II-Studie zur Bestimmung der immunmodulierenden und antiviralen Wirkungen von Iscador QuFrF bei HIV-positiven Patienten. Akademische Forschung in der anthroposophischen Medizin, Dornach 13.-15. Juni 1997, Der Merkurstab, Sonderheft Juni 1997: 31
Entspricht Z 031
- A 003** v. Wely M, Stoss M, Gorter RW: Open-label phase II trial to document immunomodulating and anti-HIV activities of Iscador QuFrF in HIV-positives. Second European Conference on Experimental AIDS Research, Stockholm, Sweden, May 31-June 3, 1997, Abstract book: 190-P4
- A 002** Gorter RW: Prospektive, longitudinale Phase-III-Studie zur Bestimmung der präventiven und krebshemmenden Wirkung von Iscador Qu Spezial bei Patientinnen mit Cervixdysplasien. Workshop "Unkonventionelle medizinische Richtungen und unkonventionelle Methoden der Krebsbekämpfung", Bad Honnef, 23.-24. Februar 1996, Forschende Komplementärmedizin 1996, 4 (1): 66
- A 001** Gorter RW, Stein J, Stoss M, Schuler C: Phase II study to document anti-HIV efficacy of Iscador QuFrF (Viscum album L.). Workshop, Europäische Akademie Nonnweiler/Trier, AIDS-Forum, 2.-3. Februar 1996